Last reviewed · How we verify

Fat degeneration of supraspinatus muscle

Applied Biologics, LLC · Phase 1 active Biologic

Fat degeneration of supraspinatus muscle is a Biologic drug developed by Applied Biologics, LLC. It is currently in Phase 1 development. Also known as: FlōGraft®, Human amniotic fluid-derived allograft.

At a glance

Generic nameFat degeneration of supraspinatus muscle
Also known asFlōGraft®, Human amniotic fluid-derived allograft
SponsorApplied Biologics, LLC
ModalityBiologic
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Fat degeneration of supraspinatus muscle

What is Fat degeneration of supraspinatus muscle?

Fat degeneration of supraspinatus muscle is a Biologic drug developed by Applied Biologics, LLC.

Who makes Fat degeneration of supraspinatus muscle?

Fat degeneration of supraspinatus muscle is developed by Applied Biologics, LLC (see full Applied Biologics, LLC pipeline at /company/applied-biologics-llc).

Is Fat degeneration of supraspinatus muscle also known as anything else?

Fat degeneration of supraspinatus muscle is also known as FlōGraft®, Human amniotic fluid-derived allograft.

What development phase is Fat degeneration of supraspinatus muscle in?

Fat degeneration of supraspinatus muscle is in Phase 1.

Related